Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Novo Reels in Replicate for New Cardiometabolic Drugs

Novo Nordisk will invest up to $550 million in Replicate Bioscience to develop RNA therapies targeting obesity and Type 2 diabetes, enhancing its pipeline amid market competition.

Summary by Pharmaphorum
Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes

3 Articles

PharmaphorumPharmaphorum
Center

Novo reels in Replicate for new cardiometabolic drugs

Replicate will receive up to $550m from Novo Nordisk in an alliance that aims to deliver a new generation of drugs for obesity and diabetes

Read Full Article
biopharmadive.combiopharmadive.com
Center

Novo strikes RNA drug deal with startup Replicate

The agreement provides research funding for Replicate and up to $550M in payments to develop medicines for diseases including obesity and diabetes.

Read Full Article
endpoints.newsendpoints.news

Novo's first obesity deal under new CEO is a $550M pact with RNA startup Replicate

For the second time this summer, Novo Nordisk is teaming up with a biotech startup from the investment firm Apple Tree Partners to create new obesity medicines. Replicate Bioscience will help the Wegovy maker develop ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biopharmadive.com broke the news in on Thursday, August 28, 2025.
Sources are mostly out of (0)

Similar News Topics

Startups icon

Startups

Medical icon

Medical

Obesity icon

Obesity

United States icon

United States

Denmark icon

Denmark

News
For You
SearchBlindspotLocal